How did the COVID-19 pandemic impact CVS Health's financial performance in the first quarter of 2020?

The COVID-19 pandemic had a mixed impact. It drove increased demand in the Pharmacy Services and Retail/LTC segments, with consumers refilling prescriptions early and increasing front store purchases. This contributed to revenue growth. However, the company also noted increased operating expenses due to pandemic-related support programs and potential future economic uncertainties.

What is the company's liquidity position and how did it manage its cash?

CVS Health ended the first quarter of 2020 with a strong liquidity position, holding $10.1 billion in cash and cash equivalents. This was bolstered by issuing $4 billion in senior notes during the quarter to enhance liquidity amidst the pandemic's economic uncertainties. Net cash provided by operating activities also saw a significant increase of 69.7% to $3.3 billion.

What is the outlook for the company's dividend payments?

The company maintained its quarterly cash dividend of $0.50 per share. Future dividend payments will depend on the company's earnings, capital requirements, financial condition, and other factors considered relevant by the Board of Directors. Despite the pandemic, the company reiterated its commitment to returning value to shareholders.

How did the company's various segments perform during the quarter?

All segments showed revenue growth. Pharmacy Services revenue increased 4.2% due to specialty pharmacy growth and increased claim volume. Retail/LTC revenue grew 7.7%, driven by prescription volume, front store sales, and brand inflation, partly influenced by COVID-19 preparations. Health Care Benefits revenue rose 7.4%, primarily from membership growth in government products and the reinstatement of the Health Insurer Fee, though net investment income declined. Corporate/Other segment revenue decreased.

CVS 10-Q Quarterly Report Q1 FY2020 — Revenue, Net Income, EPS

Summary

CVS Health Corporation reported solid revenue growth for the first quarter of 2020, with total revenues increasing by 8.3% year-over-year to $66.8 billion. This growth was driven by strong performance across all segments, notably the Pharmacy Services and Retail/LTC segments, which saw increased demand and early prescription refills due to the onset of the COVID-19 pandemic. Net income attributable to CVS Health surged by 41.2% to $2.0 billion, or $1.53 per diluted share. The company demonstrated strong operational cash flow, increasing by 69.7% to $3.3 billion, and bolstered its liquidity by issuing $4 billion in senior notes, ending the quarter with a robust cash position of $10.1 billion. The company provided significant insights into the initial impacts of the COVID-19 pandemic, noting increased demand in retail and pharmacy services, but also acknowledging potential future uncertainties and operational expense increases. Despite the challenging macroeconomic environment, CVS Health maintained its quarterly dividend and has substantial capacity under its existing share repurchase program, though no shares were repurchased in the quarter. Overall, the report indicates a strong financial performance driven by core business growth and, to some extent, the pandemic's immediate effects, while also highlighting proactive measures to manage liquidity and future uncertainties.

Financial Highlights

55 data points

Beta

Revenue

$66.75B

0.4% Gross Margin

Net Income

$2.01B

0.0% Net Margin

EPS (Diluted)

$1.53

Total Assets

$230.64B

Cash & Equivalents

$10.08B

Free Cash Flow

$2.56B

Financial Statements

Beta

Revenue	$66.75B
Cost of Revenue	$40.35B
Gross Profit	$26.41B
Operating Expenses	$63.30B
Operating Income	$3.46B
Interest Expense	$733.00M
Net Income	$2.01B
EPS (Basic)	$1.54
EPS (Diluted)	$1.53
Shares Outstanding (Basic)	1.31B
Shares Outstanding (Diluted)	1.31B

Key Highlights

1Total revenues increased 8.3% to $66.8 billion, driven by growth across all segments.
2Net income attributable to CVS Health increased 41.2% to $2.0 billion, or $1.53 per diluted share.
3Operating cash flow significantly improved, rising 69.7% to $3.3 billion.
4The company bolstered liquidity by issuing $4 billion in senior notes, ending the quarter with $10.1 billion in cash and cash equivalents.
5The COVID-19 pandemic led to increased demand in Pharmacy Services and Retail/LTC segments due to early prescription refills and higher front store volumes.
6Despite challenges, the company maintained its quarterly dividend of $0.50 per share.
7Operating expenses increased by 3.8%, partly due to the reinstatement of the Health Insurer Fee (HIF) and COVID-19 related support.

CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 31, 2020

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions